Similar articles

• Mycophenolate mofetil in living donor renal allograft recipients.

  Park K, Moon JI, Kim SI, Kim YS. Park K, et al. Transplant Proc. 1999 Feb-Mar;31(1-2):1133. doi: 10.1016/s0041-1345(98)01934-4. Transplant Proc. 1999. PMID: 10083506 Clinical Trial. No abstract available.
• Mycofenolate mofetil-cyclosporine immunosuppression of kidney transplantation recipients with two different corticosteroid doses.

  Remport A, Sasvári I, Toronyi E, Borka P, Lázár N, Járay J, Perner F. Remport A, et al. Transplant Proc. 2001 May;33(3):2302-3. doi: 10.1016/s0041-1345(01)01999-6. Transplant Proc. 2001. PMID: 11377537 Clinical Trial. No abstract available.
• Comparison of the safety and efficacy of mycophenolate mofetil, prednisolone and cyclosporine and conventional cyclosporine and prednisolone in kidney transplantation.

  Kim HC, Park SB, Kim HT, Cho WH, Park CH. Kim HC, et al. Transplant Proc. 2000 Nov;32(7):1751-2. doi: 10.1016/s0041-1345(00)01391-9. Transplant Proc. 2000. PMID: 11119919 Clinical Trial. No abstract available.
• Mycophenolate mofetil for the transplanted kidney?

  [No authors listed] [No authors listed] Drug Ther Bull. 1997 May;35(5):38-40. doi: 10.1136/dtb.1997.35538. Drug Ther Bull. 1997. PMID: 9282420 Review.
• [Mycophenolate mofetil in comparison with other immunosuppressive drugs].

  Schnülle P, van der Woude FJ. Schnülle P, et al. Internist (Berl). 1998 Aug;39(8):879-86. doi: 10.1007/s001080050256. Internist (Berl). 1998. PMID: 9757398 Review. German. No abstract available.